<DOC>
	<DOCNO>NCT02402595</DOCNO>
	<brief_summary>The purpose study determine effect potent CYP3A4 inhibitor , itraconazole , steady-state PK AVP-923 AVP-786 .</brief_summary>
	<brief_title>Drug Interaction Study Between AVP-923 Itraconazole Between AVP-786 Itraconazole Healthy Adult Subejcts</brief_title>
	<detailed_description>A Phase 1 , single-center , randomize , double-blind , double-dummy drug interaction study .</detailed_description>
	<mesh_term>Dextromethorphan</mesh_term>
	<mesh_term>Quinidine</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>Healthy adult male female , 18 55 year age Body Mass Index ( BMI ) ≥19 ≤30 kg/m2 ( male female ) History presence significant disease History substance abuse dependence ( except caffeine ) , treatment substance use disorder ( ) within year prior screen within 6 month nicotine include ecigarettes Use tobaccocontaining nicotinecontaining product within 6 month prior first dose Use prescription overthecounter medication within 14 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Drug-drug interaction</keyword>
	<keyword>Healthy Volunteers</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>deuterated dextromethorphan</keyword>
	<keyword>dextromethorphan</keyword>
	<keyword>dextromethorphan quinidine</keyword>
	<keyword>deuterated dextromethorphan quinidine</keyword>
	<keyword>itraconazole</keyword>
</DOC>